Physician profile
Jenna N Kopp
NPI 1851023345
$141,044.70
in general payments reported to CMS, 2019-2025
30 companies · $90K in 2025
The $90K reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $1,104 · 2023: $11K · 2024: $39K · 2025: $90K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Travel and Lodging: $31K · Food and Beverage: $9,907 · Consulting Fee: $5,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,321.86 |
| Travel and Lodging | $31,324.25 |
| Food and Beverage | $9,907.40 |
| Consulting Fee | $5,100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $59,355.96 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $41,290.01 | 2022-2025 | |
| Lilly USA, LLC | $35,615.96 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $1,888.25 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $489.74 | 2022-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $366.15 | 2022-2025 | |
| Gilead Sciences, INC. | $264.28 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $223.86 | 2023-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $218.83 | 2022-2025 | Dupixent |
| Amgen INC. | $148.90 | 2022-2025 | Uplizna |
| Ferring Pharmaceuticals INC. | $139.70 | 2023 | Rebyota |
| Madrigal Pharmaceuticals | $139.13 | 2025 | Rezdiffra |
| Celgene Corporation | $138.28 | 2021-2023 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $122.75 | 2021 | |
| Pfizer INC. | $110.45 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $86.04 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $65.86 | 2024 | Stelara |
| Organon LLC | $54.08 | 2023-2025 | Hadlima |
| Qol Medical, LLC | $53.71 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.91 | 2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $37.60 | 2023-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $35.97 | 2025 | Voquezna |
| Pharmacosmos Therapeutics INC. | $31.42 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $27.63 | 2025 | Iqirvo |
| Alnylam Pharmaceuticals INC. | $21.25 | 2025 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.57 | 2023 | Cyltezo |
| Celltrion USA INC. | $15.51 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $14.69 | 2023 | Injectafer |
| Ironwood Pharmaceuticals, INC | $14.54 | 2023 | Linzess |
| Baxter Healthcare | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Kopp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.